Karim Bandali, PhD’s Post

Greetings from Tokyo where our Medtronic Cardiac Surgery CMO Professor Pieter Kappetein and I are at the first Avalus Ultra™ bioprosthesis implant in Japan! There are no words to express the impact Pieter’s contributions have had on patients around the world as a cardiac surgeon, CMO and patient advocate. I am proud to call him our CMO, my mentor and true friend. If you have not read my article on the Avalus Ultra valve, you can find it here: https://lnkd.in/g-4eKvu5. Surgeons around the world have been impressed by the ease of use at implant,ᶦᵛ and straightforward sizing to determine the right valve fit. Our innovative aortic tissue valve incorporates the proven features of the first-generation Avalus bioprosthesis. According to Avalus data, it has demonstrated industry leading Effective Orifice Area (EOA), and excellent durability data.ᶦ·ᶦᶦ·ᶦᵛ With our launch fully underway now in both the USA and Japan, we now set our eyes on Western Europe to expand our impact for patients! My heartfelt thanks to Pieter for being our game changer for patients! #Medtronic #CardiacSurgery #AvalusUltra #Innovation #HealthcareTechnology #WithEveryBeatExpectMore #medtronicemployee ᶦ Klautz RJM, Dagenais F, Reardon MJ, Lange R, Moront MG, Labrousse L et al. Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes. Eur J Cardiothorac Surg 2022 Aug 3;62(3) ᶦᶦ Klautz RJM, Rao V, Reardon MJ, et al. Examining the typical hemodynamic performance of nearly 3000 modern surgical aortic bioprostheses. Eur J Cardiothorac Surg. Published online May 6, 2024.  ᶦᵛ Based on internal test report D00998354, Avalus Ultra HFE Design Validation Test Report.

We are firmly committed to designing valves fit for the future right from the start. Learn more about how our new Avalus Ultra valve was engineered based on customer feedback. #Medtronic #CardiacSurgery #AvalusUltra #Innovation #PatientCare #SurgicalValve #HealthcareTechnology 

My hometown of Toronto provided the perfect backdrop to welcome Geoff Martha to #AATS24 to meet a global group of cardiac surgeons. Together, we had much to celebrate - the importance of cardiac surgeons to the beginnings of Medtronic, the U.S. launch of the Avalus Ultra™ valve, and Medtronic’s 75th anniversary as a company that marks the genesis of the MedTech industry. Geoff and I spent time listening to some of the most influential surgeons, both early career and experienced leaders. We learned patients are becoming more complex and that a comprehensive, innovative portfolio is what a surgeon needs today and in the future. We are more committed than ever to driving innovation and making the investments needed to advance and deliver optimal cardiac surgical care. In the last 12 months, we’ve been proud to bring you our new Penditure™ Left Atrial Appendage Exclusion System, broad-based investments in supply reliability, such as for cannula and oxygenators, Avalus™ 29mm, and clinical data of the largest cohort of contemporary bioprosthetic aortic valves with 1-year echocardiograms analyzed by a single core lab showing best-in-class EOA and market-leading PPM for the Avalus platform. And we’re not even close to done yet… Stay tuned; the future has never been brighter at Medtronic Cardiac Surgery. #Medtronicemployee #CardiacSurgery #Medtronic #witheverybeatexpectmore

This week at #AATS24, we are unveiling Medtronic Cardiac Surgery's new value statement, “With Every Beat, Expect More.” https://lnkd.in/dKJVkdDT   With this as our global promise, we will strive to be your partner of choice, that delivers a strong cadence of innovation across the full continuum of cardiac surgical therapies that are required to help treat the growing complexity of the patients you serve. Come see us at booth #705 at AATS, where we can discuss what this promise means to you. Our journey to serve over 6 million patients in the next five years, starts today!   Our future has never been brighter at Medtronic Cardiac Surgery. A GREAT company, with GREAT people, driving GREAT results for patients around the world. #Medtronicemployee #CardiacSurgery #Medtronic #witheverybeatexpectmore

I am incredibly excited to announce the U.S. launch of the Avalus Ultra™ valve.    As patient needs become more complex, cardiac surgeons told us they wanted more advanced technologies to meet these evolving needs. The Avalus Ultra valve is our next generation surgical aortic tissue valve, which was designed to address this feedback. With the Avalus Ultra valve, surgeons will see their voice come to life in the ease of use at implant,¹·² straightforward sizing for the right valve fit, and clear visibility for future valve-in-valve procedure.³·⁴ This next generation device also builds on the Avalusᵀᴹ valve’s long-term durability and trusted performance to serve patients over their lifetime.⁵·⁶⋅⁷   I’m so proud of our Medtronic team, who demonstrate their deep commitment to our customers and patients every day. The Avalus Ultra launch reflects our focused strategy of both driving innovation and making the investments needed to advance and deliver optimal cardiac surgical care.   #MedtronicEmployee #CardiacSurgery #AorticStenosis #SAVR Risks may include infection, surgical complications, stroke, endocarditis, and death.  https://lnkd.in/gNNUFgDi   ¹Based on internal test report D00998354, Avalus Ultra HFE Design Validation Test Report. ² Based on internal document D00437207, Avalus Ultra Design Concept. ³ Based on internal test report D00998354, Avalus Ultra HFE Design Validation Test Report. ⁴ Based on internal document D00437207, Avalus Ultra Design Concept ⁵ Klautz RJM, Dagenais F, Reardon MJ, Lange R, Moront MG, Labrousse L et al. Surgical aortic valve replacement with a stented pericardial bioprosthesis: 5-year outcomes. Eur J Cardiothorac Surg 2022 Aug 3;62(3) ⁶ Klautz RJM, Rao V, Reardon MJ, et al. Hemodynamic function of contemporary surgical aortic valves 1-year postimplant. Abstract presented at: 37th Annual Meeting of the European Association for Cardio-Thoracic Surgery; October 4-7, 2023; Vienna, Austria. ⁷ Sohn SH, Kang Y, Kim JS, et al., A Randomized Trial Comparing One-year Hemodynamics of Two Bovine Pericardial Valves. Thorac Cardiovasc Surg. 2023 Dec 5

I am looking forward to attending this year’s AATS meeting. We have some very exciting things planned. Be sure to stop by and see us at booth #705   #AATS2024 #Medtronic #witheverybeatexpectmore #Medtronicemployee

I had the incredible opportunity to spend time with Husam H Balkhy (Dr. Balkhy) and his team at the University of Chicago. A learning experience that will not be forgotten soon. Understanding new perspectives of what Cardiac Surgeons need to advance care for their patients. Medtronic Cardiac Surgery is committed to bringing a strong cadence of innovation that addresses the complexity of cardiovascular disease while providing patients with minimally invasive options during life saving cardiac surgical interventions. #medtronicemployee

I wanted to share this special moment from The 2024 Polar Plunge for Special Olympics Minnesota with my Medtronic Cardiac Surgery Team. I wish to thank all my sponsors for their incredible support of my plunge! My sincere and special thanks also to Neil Nye and Laura Skadsberg for their pure awesomeness and spirit getting us all organized as a team and making this such a memorable event for all. To my team and fellow plungers, I am so incredibly proud of how each of you live every tenet of our Medtronic Mission. #medtronicemployee #mdtproud